Aegis Capital Comments on Valeant Pharma (VRX) Following Q1 Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/23/2026

1. USO
2. META
3. NVDA
4. DCOY
5. SPY
6. MSFT
7. VKTX
8. PRGS
9. CMPX
10. GS

Go back to Aegis Capital Comments on Valeant Pharma (VRX) Following Q1 Results

Valeant Pharmaceuticals International, Inc. (VRX) Tops Q1 EPS by 4c

May 8, 2014 6:03 AM EDT

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) reported Q1 EPS of $1.76, $0.04 better than the analyst estimate of $1.72. Revenue for the quarter came in at $1.85 billion, versus $1.04 billion reported last year.

"Our first quarter results demonstrate the strong, durable nature of our diversified business model," stated J. Michael Pearson, chairman and chief executive... More